A multicenter, randomized, double-blind, placebo and escitalopram controlled trial of the safety and efficacy of BMS-562086 [pexacerfont] in the treatment of outpatients with major depressive disorder

Trial Profile

A multicenter, randomized, double-blind, placebo and escitalopram controlled trial of the safety and efficacy of BMS-562086 [pexacerfont] in the treatment of outpatients with major depressive disorder

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2007

At a glance

  • Drugs Escitalopram; Pexacerfont
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Dec 2007 The expected completion date for this trial is now 1 Oct 2007.
    • 14 Dec 2007 Status change from in progress to completed.
    • 31 Jul 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top